RELATIVE PROGRESSION-FREE SURVIVAL OVER TIME OF NOVEL TRIPLET REGIMENS FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Betts, K. [1 ]
Chen, C. [2 ]
Zichlin, M. [1 ]
Brun, A. [2 ]
Signorovitch, J. [1 ]
Makenbaeva, D. [2 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Bristol Myers Squibb Inc, Plainsboro, NJ USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1300
引用
收藏
页码：533 / 533
页数：1
相关论文
共 50 条
  • [21] Progression-Free Survival in Third-Line Treatment of Relapsed/Refractory Multiple Myeloma Among Patients with Who Have Received Prior Bortezomib and Immunomodulatory Drugs
    Jagannath, Sundar
    Roy, Anuja
    Kish, Jonathan K.
    Globe, Denise
    Lunacsek, Orsolya
    Eaddy, Michael T.
    Kuriakose, Emil T.
    Willey, Joanne
    Siegel, David
    BLOOD, 2015, 126 (23)
  • [22] Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
    Fostier, Karel
    De Becker, Ann
    Schots, Rik
    ONCOTARGETS AND THERAPY, 2012, 5 : 237 - 244
  • [23] Impact of Race on Progression-Free Survival and Overall Survival in Patients with Multiple Myeloma
    Wani, Kashmira
    Gutta, Radhika
    Mittal, Aayush
    Jamil, Maria
    Springer, Kylie
    Kuriakose, Philip
    BLOOD, 2023, 142
  • [24] Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States
    Sanchez, Larysa
    Chari, Ajai
    Cheng, Mu
    Cherepanov, Dasha
    DerSarkissian, Maral
    Stull, Dawn Marie
    Huang, Fei
    Hilts, Annalise
    Chun, Justin
    Duh, Mei Sheng
    Ailawadhi, Sikander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S187 - S187
  • [25] Combination Therapy with Isatuximab in relapsed multiple Myeloma Superior progression-free Survival and clinically meaningful Depth of Response
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (05)
  • [26] Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma
    Kowalski, Andrew
    Coffey, David G.
    Diamond, Benjamin
    Hoffman, James E.
    Kaddoura, Marcella
    Lykon, Jill
    Maura, Francesco
    Rodriguez-Martinez, Yahirini
    Rosen, Suzan
    Shah, Faika
    Verducci, Dennis
    Landgren, Ola
    Kazandjian, Dickran
    BLOOD, 2024, 144 : 2389 - 2390
  • [27] Pomalidomide-Containing Regimens (PCR) for the Treatment of Relapsed and Refractory Multiple Myeloma
    Jimenez-Zepeda, Victor H.
    Venner, Christopher P.
    Belch, Andrew
    Sandhu, Irwindeep
    Nikitina, Tatiana
    Hewitt, Joanne D.
    Duggan, Peter
    Neri, Paola
    Rashid-Kolvear, Fariborz
    Bahlis, Nizar J.
    BLOOD, 2015, 126 (23)
  • [28] African American relapsed/refractory multiple myeloma patients have a progression free survival benefit with selinexor treatment in the STORM study
    Cole, Craig
    Opalikhin, Anne
    McCartney, Matthew
    Heideman, Caroline
    Pentapati, Swetha
    Wang, Ling
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S168 - S169
  • [29] The Impact of Focal Lesions on Overall and Progression-free Survival in Multiple Myeloma
    Kirkizlar, Tugcan Alp
    Kirkizlar, Onur
    Soyluoglu, Selin
    Umit, Elif Gulsum
    Ustun, Funda
    Demir, Ahmet Muzaffer
    INDIAN JOURNAL OF NUCLEAR MEDICINE, 2024, 39 (05): : 353 - 359
  • [30] MPT improves progression-free survival in elderly patients with multiple myeloma
    不详
    Nature Clinical Practice Oncology, 2009, 6 (1): : 4 - 4
12345